People: Vical Inc (VICL.O)

VICL.O on Consolidated Issue listed on NASDAQ Global Market

2.89USD
9 Feb 2010
Price Change (% chg)

$-0.10 (-3.34%)
Prev Close
$2.89
Open
--
Day's High
$3.01
Day's Low
$2.87
Volume
352,394
Avg. Vol
382,105
52-wk High
$5.51
52-wk Low
$1.38

view people for:

Summary

Name Age Since Current Position
Douglas, R. Gordon 75 1999 Chairman of the Board
Samant, Vijay 56 2000 President, Chief Executive Officer, Director
Broadfoot, Jill 47 2009 Chief Financial Officer, Senior Vice President, Secretary
Rolland, Alain 49 2009 Executive Vice President - Product Development
Jackman, Robin 39 2006 Senior Vice President - Business Operations
Bracken, Kevin 60 2001 Vice President - Manufacturing
Smith, Larry 48 2006 Vice President - Vaccine Research
De Guttadauro, Andrew 42 2007 Vice President - Corporate Development
Kenney, Richard 2010 Vice President - Clinical Development
Lyons, Gary 58 1997 Director
Merton, Robert 64 2002 Director
Campbell, Robert 72 2003 Director
» Insider Trading

Biographies

Name Description
Douglas, R. Gordon Dr. R. Gordon Douglas, M.D., is Chairman of Vical Incorporated. He is an Adjunct Professor of Medicine at Cornell University Medical College. Dr. Douglas retired in April 1999 from Merck, where he had been President of the Merck Vaccine Division since 1991 and a member of the Merck Management Committee. Prior to joining Merck in 1989, Dr. Douglas was a physician and academician. His teaching and administrative affiliations included Baylor College of Medicine, University of Rochester School of Medicine, and Cornell University Medical College. His medical practice included affiliations with The New York Hospital, Memorial Sloan-Kettering Cancer Center, The Rockefeller University Hospital and North Shore University Hospital. Dr. Douglas has served as a visiting professor at a number of medical schools and as a consultant to several pharmaceutical and biomedical companies. He also served on the board of directors of the IAVI and is currently a member of the board of directors of Advancis Pharmaceutical Corporation, EluSys Therapeutics, Inc., IOMAI Corporation and VaxInnate Corporation, all biotechnology or biopharmaceutical companies. In addition, Dr. Douglas is the Chairman of the Aeras Global TB Vaccine Foundation and was formerly Director of Strategic Planning at the National Institutes of Health, Dale and Betty Bumpers Vaccine Research Center. He holds a bachelor’s degree from Princeton University and an M.D. degree from Cornell University Medical College. Dr. Douglas received his medical staff training at The New York Hospital and Johns Hopkins Hospital and is Board Certified in Internal Medicine. He is a member of the Institute of Medicine, the Association of American Physicians, the Infectious Diseases Society of America and numerous other organizations.
Samant, Vijay Mr. Vijay B. Samant joined Vical Incorporated as President and Chief Executive Officer in November 2000. Previously, he held various positions at Merck, from 1977 to 2000. From 1998 to 2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. From 1977 to 1990, Mr. Samant held a variety of positions of increasing responsibility in manufacturing, process engineering, production planning and control, business development and loss prevention in several Merck operating divisions. Mr. Samant holds a bachelor’s degree in chemical engineering from the University of Bombay, India, an M.S. degree in chemical engineering from Columbia University and an M.B.A. degree from the Sloan School of Management at the Massachusetts Institute of Technology. Mr. Samant is a director of the Aeras Global TB Vaccine Foundation, a not-for-profit organization working to develop tuberculosis vaccines, serves on the Project Management Subcommittee of the International AIDS Vaccine Initiative and is on the Board of Trustees of the National Foundation for Infectious Diseases and the International Vaccine Institute in Seoul, South Korea.
Broadfoot, Jill Ms. Jill M. Broadfoot joined Vical Incorporated as Vice President, Chief Financial Officer and Secretary in October 2004 and was named Senior Vice President, Chief Financial Officer and Secretary in January 2009. From February 1999 until joining Vical Inc, Ms. Broadfoot held various positions at DJO Incorporated, a publicly-traded medical device company, most recently as Vice President of Finance and Controller with broad responsibilities in finance, accounting, treasury, risk management, and corporate governance. From September 1994 until joining DJO Incorporated, Ms. Broadfoot served as an audit manager at Ernst & Young LLP, where her clients included life sciences, computer software and telecommunications companies as well as government contractors. From June 1990 until joining Ernst & Young, she was Division Controller at Medical Imaging Centers of America, Inc., a chain of freestanding imaging centers and mobile imaging centers, where she held divisional accounting and financial reporting responsibilities. Ms. Broadfoot received her bachelor’s degree in business administration and accounting from San Diego State University, and is a Certified Public Accountant.
Rolland, Alain Dr. Alain P. Rolland, Pharm.D., Ph.D., joined Vical Incorporated as Vice President, Product Development in August 2002. He was named Senior Vice President, Product Development in April 2004 and Executive Vice President, Product Development in January 2009. Dr. Rolland was Senior Vice President of Pre-Clinical Research and Development, and Head of The Woodlands Center of Valentis, Inc. from 2000 to 2002. From 1993 to 1999, he served in several positions at a predecessor company to Valentis, Inc., GeneMedicine, Inc., where he progressed from Director of Gene Delivery to Vice President of Research. From 1989 to 1993, he was the Head of Formulation Research at the Research & Development Center of Galderma International in France. Prior to that, he was a scientist at the Advanced Drug Delivery Research Center of Ciba Geigy Pharmaceuticals in the United Kingdom. He received his Pharm.D., D.E.A., and Ph.D. degrees from Rennes University, France. Dr. Rolland holds several U.S. and European patents on advanced drug and gene delivery for medical applications. He has authored numerous publications and books in the area of nonviral gene delivery resulting from his active career in research and development. He also serves on the editorial board of several journals and as the Editor-in-Chief of “Current Pharmaceutical Biotechnology.”
Jackman, Robin Dr. Robin M. Jackman, Ph.D., joined Vical Incorporated as Vice President, Business Development in June 2004 and was named Senior Vice President, Business Operations in June 2006. Since 2002, Dr. Jackman had been Vice President of Corporate Development at Sequenom, Inc., a public company focused on developing genetic analysis products, where he focused primarily on business development and investor relations. From 1998 to 2002, he served in positions of increasing responsibility within the Life Sciences Investment Banking group at Robertson Stephens, culminating as Vice President. While at Robertson Stephens, he managed a broad range of transactions for biotechnology, medical device, and emerging pharmaceutical companies with an aggregate transaction value over $11 billion. Dr. Jackman received a Ph.D. in immunology from Harvard University, and a master’s degree in medicine from Harvard Medical School, during which time he was a biomedical consultant to the investment community. He began his career as a research associate at Protein Design Labs. Dr. Jackman received a bachelor’s degree with honors in biological science from Stanford University.
Bracken, Kevin Mr. Kevin R. Bracken joined as Vice President, Manufacturing of Vical Incorporated in October 2001. From July 1998 to October 2001, Mr. Bracken was Vice President, Process Engineering and Manufacturing for Universal Preservation Technologies, Inc., and from November 1995 to July 1998, he was Director of Engineering for Molecular Biosystems, Inc. Prior to November 1995, he held a variety of process and engineering positions with Gilead Sciences, Inc., and a predecessor company, Vestar, Inc., with Baxter International, and with E.I. duPont de Nemours and Company. He brings experience in commercial scale-up of biopharmaceutical manufacturing facilities, process development and optimization, and direction of research, pre-clinical and clinical production and contract manufacturing. Mr. Bracken earned his M.S. degree in chemical engineering from the University of Rochester in 1973, and his B.S. degree in chemical engineering from the University of Delaware in 1970.
Smith, Larry Dr. Larry R. Smith, Ph.D., joined as Executive Director, Vaccinology of Vical Incorporated in September 2003, and was named Vice President, Vaccine Research in October 2006. Prior to joining Vical, Dr. Smith was Director of Viral Vaccines Research at Wyeth Vaccines, where he oversaw the immunogenicity testing of various viral vaccines including a number of recombinant viral vectors. Prior to joining Wyeth in 1996, Dr. Smith was a Scientific Investigator at Immune Response, where he identified autoreactive T-cell targets in psoriasis and multiple sclerosis which led to the clinical testing of several therapeutic vaccine candidates. Dr. Smith received a B.S. degree in Biology from Purdue University, a Ph.D. in Microbiology and Immunology from the University of Texas Medical Branch, and was a postdoctoral fellow in the Immunology Department at Scripps Clinic and Research Foundation.
De Guttadauro, Andrew Mr. Andrew R. De Guttadauro joined as Vice President, Corporate Development of Vical Incorporated in August 2007. Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec, Inc., a public biotechnology company, since February 2007, following a two-year assignment overseeing the commercial development of that company’s product Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, a public pharmaceutical company, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Prior to joining MedImmune, Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceutical Products, Inc., where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the U.S. Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.
Kenney, Richard Dr. Richard T. Kenney, M.D., has been appointed as Vice President - Clinical Development of Vical Incorporated. Prior to joining Vical, Dr. Kenney held key positions in influenza and biodefense vaccine development at GSK Biologicals (formerly ID Biomedical) from 2005 to 2009, most recently as Senior Director of Global Clinical R&D, Vaccines for Viral Diseases. His initial role at ID Biomedical was Vice President, Clinical & Regulatory Affairs. From 2001 to 2005, he served as Vice President, Clinical Development and then as Vice President, Medical & Regulatory Affairs at IOMAI Corporation. Dr. Kenney advanced through several positions from 1995 to 2001 as a researcher/reviewer at the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), Office of Vaccine Research and Review (OVRR). He simultaneously practiced internal medicine at Kaiser Permanente After Hours Care from 1988 to 2001. After completing his residency in internal medicine at Duke University Medical Center, Dr. Kenney pursued postdoctoral training at the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), completing a fellowship in infectious diseases, and then in molecular parasitology and tropical medicine. He received board certifications in Internal Medicine and Infectious Diseases. He earned his M.D. degree at Harvard Medical School, and graduated with special honors from George Washington University. Dr. Kenney has authored or co-authored more than 50 scientific papers and book chapters, has received multiple awards, is a fellow in the American College of Physicians and in the Infectious Disease Society of America, and has been a member of several professional organizations including the American Federation for Medical Research and the American Society of Tropical Medicine & Hygiene.
Lyons, Gary Mr. Gary A. Lyons is Director of Vical Incorporated. He held various positions with Neurocrine Biosciences, Inc., a biopharmaceutical company, for 15 years through January 2008, including President and Chief Executive Officer. From 1983 to 1993, Mr. Lyons held various executive positions at Genentech, Inc., a biotechnology company, including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing. From 1973 to 1983, Mr. Lyons worked with American Critical Care, a division of American Hospital Supply Corporation, serving as Director of Sales from 1980 to 1983. He is also a director of Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc., publicly held biotechnology companies. Mr. Lyons holds a bachelor’s degree in marine biology from the University of New Hampshire and an M.B.A. degree from Northwestern University, JL Kellogg Graduate School of Management.
Merton, Robert Dr. Robert C. Merton, Ph.D., is Director of Vical Incorporated. He has been a professor at the Harvard Business School since 1988, and is currently the John and Natty McArthur University Professor. Prior to his positions at Harvard, he served on the finance faculty of the Massachusetts Institute of Technology’s Sloan School of Management from 1970 until 1988. Dr. Merton received the Alfred Nobel Memorial Prize in Economic Sciences in 1997 for a new method to determine the value of derivatives. Dr. Merton is past President of the American Finance Association and a member of the National Academy of Sciences. He is a director of the funds managed by Dimensional Fund Advisors, one of our stockholders. Until September 2008, Dr. Merton was also a director and the Chief Science Officer of Trinsum, created in 2007 by a merger of Marakon Associates and Integrated Finance Limited, a specialized investment bank he co-founded in 2002, and a director of MF Risk, Inc., a financial risk corporation, Community First Financial Group and Peninsula Banking Group. He serves on advisory boards of several companies and institutions. Some of Dr. Merton’s other financial and accounting experience includes serving as a Senior Advisor to and Managing Director of JP Morgan Chase & Co. from 1999 to 2001, and a co-founder and principal of Long-Term Capital Management, L.P. He has received numerous academic awards and has lectured widely. Dr. Merton holds a bachelor’s degree from Columbia University, an M.S. degree in applied mathematics from the California Institute of Technology, and a Ph.D. degree in economics from the Massachusetts Institute of Technology. In addition, Dr. Merton holds numerous honorary degrees.
Campbell, Robert Mr. Robert H. Campbell is Director of Vical Incorporated. He held various positions with Sunoco, Inc., a publicly traded petroleum refiner and chemicals manufacturer, for 40 years through June 2000, including President, Chief Executive Officer and Chairman of the Board. In 1999, while Mr. Campbell was Chairman of Sunoco, the company won the “Board Excellence Award” from Spencer Stuart and the Wharton School of Business of the University of Pennsylvania. In 2001, Mr. Campbell was named one of “Corporate America’s Outstanding Directors” by the editors of “Corporate Alert.” In addition, he was invited to testify as an expert on corporate governance issues in May 2002, before the U.S. Senate Permanent Subcommittee on Investigations in the hearings on Enron Corp. and Arthur Andersen LLP. Mr. Campbell serves as Chairman of the Board for The Pew Charitable Trusts, a charitable foundation, and as a member of the board of directors of CIGNA Corporation, an employee benefits company. Mr. Campbell also serves as a director of the Robert H. Campbell and Nancy W. Campbell Foundation, a vehicle to contribute to charitable causes. Mr. Campbell received a bachelor’s degree in chemical engineering with honors from Princeton University, a master’s degree in chemical engineering from Carnegie Mellon University and a master’s degree in management through the Sloan Fellows program at the Massachusetts Institute of Technology.

Basic Compensation

Name Fiscal Year Total
Douglas, R. Gordon --
Samant, Vijay 1,183,140
Broadfoot, Jill 539,123
Rolland, Alain 498,919
Jackman, Robin --
Bracken, Kevin 238,510
Smith, Larry --
De Guttadauro, Andrew --
Kenney, Richard --
Lyons, Gary --
Merton, Robert --
Campbell, Robert --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Douglas, R. Gordon 0 0
Samant, Vijay 750,000 163,499
Broadfoot, Jill 750,000 163,499
Rolland, Alain 0 0
Jackman, Robin 0 0
Bracken, Kevin 65,000 0
Smith, Larry 0 0
De Guttadauro, Andrew 0 0
Kenney, Richard 0 0
Lyons, Gary 0 0
Merton, Robert 0 0
Campbell, Robert 0 0

Insider Trading

Name Shares Traded Price
SAMANT VIJAY B 120,000 $0.01
CHURCH JILL MARIE 50,000 $0.01
ROLLAND ALAIN P 50,000 $0.01
ROLLAND ALAIN P 3,073 $3.45
SAMANT VIJAY B 439 $3.28
ROLLAND ALAIN P 368 $3.28
ROLLAND ALAIN P 131 $3.33
SAMANT VIJAY B 658 $3.33
ROLLAND ALAIN P 109 $3.41
SAMANT VIJAY B 427 $3.96
ROLLAND ALAIN P 128 $4.03
SAMANT VIJAY B 641 $4.03
ROLLAND ALAIN P 107 $3.90
AUSTIN W MARXE ET AL 150,000 $3.61
AUSTIN W MARXE ET AL 25,000 $3.46
AUSTIN W MARXE ET AL 126,200 $3.56
AUSTIN W MARXE ET AL 200,000 $3.45
AUSTIN W MARXE ET AL 50,000 $3.51
AUSTIN W MARXE ET AL 100,000 $3.18
AUSTIN W MARXE ET AL 50,000 $3.17
AUSTIN W MARXE ET AL 100,000 $3.16
SAMANT VIJAY B 427 $2.49
ROLLAND ALAIN P 128 $2.53
SAMANT VIJAY B 640 $2.53
ROLLAND ALAIN P 106 $2.53
» Full list on Insider Trading
view people for: